Hot Topics - Page 3 - Ancell Corporation

Exosomes increase PD-L1 expression and induce tolerance to NIMA

A University of WI Madison research group used Ancell antibodies to analyze exosomes involved in the induction of tolerance to non-inherited maternal antigens(NIMA). This could have implications for allogeneic graft tolerance./ “Cross-Decoration of Dendritic Cells by Non-Inherited Maternal Antigen-Containing Extracellular Vesicles: Potential Mechanism for PD-L1-Based Tolerance in Cord Blood and Organ Transplantation”Diego A. Lema, A […]

Exosomes increase PD-L1 expression and induce tolerance to NIMA Read More »

Anti-TRBC1 (TCR Cb1) antibody indicates clonality in T-ALL

In a Mayo Clinic study, the blood from 19 T-ALL patients were compared to 24 normal samples using a flow cytometric panel. While the normal samples all showed a “characteristic and reproducible” pattern of cellsurface expressed CD3 and TRBC1 positivity, the leukemic samples were either almost entirely TRCB1 positive or almost entirely negative, indicating T

Anti-TRBC1 (TCR Cb1) antibody indicates clonality in T-ALL Read More »

HIV Particles sorted from CSF of ARV patients

Ancell anti-CD26 and anti-CD36 biotinylated antibodies used to capture HIV Virions from CSF of patients undergoing ARV treatment. The markers on sorted virions correlate with host cellular origin. “T cell derived HIV-1 is present in the CSF in the face of suppressive anti-retroviral therapy” G Lustig, A Sigal, et al. (Sep 2021) PLoS Pathog 17(9):

HIV Particles sorted from CSF of ARV patients Read More »

Ancell anti-CD63 antibody used to capture Tumor Extracellular Vesicles from Colorectal Cancer patient plasma in a high throughput device

The device captures EV from plasma and analyzes clinically relevant tumour biomarkers (EGFR, EpCAM, CD24 and GPA33) of colorectal cancer (CRC). The results were predictive of disease severity and prognosis for the test subjects. “An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma” Jongmin Park, Hakho Lee, et al.

Ancell anti-CD63 antibody used to capture Tumor Extracellular Vesicles from Colorectal Cancer patient plasma in a high throughput device Read More »

Neutrophil Trogocytosis blocked by Ancell anti-CD18 mAb and F(ab’)2 reagents in a CD47-SIRPa checkpoint disrupted model

The use of Neutrophils from FERMT3 patients elucidated the requirement of kindlen3-CD18 interaction for synapse formation and trogocytosis of antibody opsinized SIRPa-CD47 checkpoint disruped cancer cells in vitro. “Kindlin3-Dependent CD11b/CD18-Integrin Activation IsRequired for Potentiation of Neutrophil Cytotoxicity byCD47–SIRPa Checkpoint Disruption” Panagiota Bouti, Timo K. van den Berg, et al. (Dec 2020) Cancer Immunology Research Priority

Neutrophil Trogocytosis blocked by Ancell anti-CD18 mAb and F(ab’)2 reagents in a CD47-SIRPa checkpoint disrupted model Read More »

TRCB1 (T cell Receptor C Beta 1) is proving to be an increasingly useful cell surface marker in identification of T cell subsets and T cell malignancies

“Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms” H Berg, H Olteanu, et al. (May 2021) Clinical Cytometry 100(3): 361-369. https://doi.org/10.1002/cyto.b.21881 Ancell anti-human TRCB1 (Clone JOVI-1) reagents: 101-020 Purified (with Preservative) 101-820 Purified

TRCB1 (T cell Receptor C Beta 1) is proving to be an increasingly useful cell surface marker in identification of T cell subsets and T cell malignancies Read More »

TIGIT blockade restores T cell function in pancreatic cancer model

Blockade of CD155/TIGIT signaling in conjunction with PD-1 blockade and CD40 agonism restores T cell function in mouse pancreatic cancer model “The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer” Freed-Pastor WA, Tyler Jacks, et al. (July 2021) Cancer Cell S1535-6108(21)00384-6. doi: 10.1016/j.ccell.2021.07.007 Relevant Ancell Immunology tools anti-human TIGIT mAb Recombinant human

TIGIT blockade restores T cell function in pancreatic cancer model Read More »

Recombinant CD304(Neuropilin) now availible!

Highly active recombinant CD304-muIg protein now available from Ancell! Ancell HEK cell derived CD304-muIg binds in EIA to immobilized VEGF165. CD304 references “CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia” Pratyusha Gudapati Prashant R Tembhare , et al. (2020 Jul) Cytometry B Clin Cytom.

Recombinant CD304(Neuropilin) now availible! Read More »

Shielded Redirected Adenovirus (SHREAD) effective to deliver therapeutic drug expression construct directly into tumor cells

Researchers from University of Zurich and California Institute of Technology utilize an Adenovirus 5 virion with anti-HER2 TZB antibody (Herceptin) expressing payload to treat orthotopic human HER2 positive tumors in mice. Virion was modified with bispecific multivalent DARPin with external specificity to HER2 receptor, and shielded with scFV directed to coagulation factor X-binding sites on

Shielded Redirected Adenovirus (SHREAD) effective to deliver therapeutic drug expression construct directly into tumor cells Read More »

Significance of Serum Antibodies in COVID-19 patients

A Danish study1 in JI showed that the serum titer of anti-SARS-CoV-2 IgG, IgA and IgM antibodies in COVID-19 patients correlated with disease severity. “…Abs toward SARS-CoV-2 represent a double-edged sword…” In a Turkish study2 (also published in JI) of recovered COVID-19 patients, 20% did not have significant levels of SARS-CoV-2 neutralizing antibodies. This cohort

Significance of Serum Antibodies in COVID-19 patients Read More »